Georgetown University Lombardi Comprehensive Cancer Center Support Grant

乔治城大学隆巴迪综合癌症中心支持补助金

• 批准号: 10771760
• 负责人: Louis M. Weiner
• 金额: $ 234万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-31 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10771760
• 关键词: Address; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Survivorship; Capital; Caring; Catchment Area; Cell Therapy; Clinical; Clinical Research; Clinical Trials; Communities; Comprehensive Cancer Center; County; Data Science; Direct Costs; Disparity; Education; Ensure; Excess Mortality; Funding; Future; Growth; Health; Hematologic Neoplasms; Immunotherapy; Intervention; Investigational Therapies; Lead; Link; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Maryland; Meridians; Mission; NCI Center for Cancer Research; Paper; Patient Care; Persons; Policies; Population; Process; Publishing; Research; Scientist; Strategic Planning; Translational Research; Universities; Virginia; Vision; Washington; Work; anticancer research; base; cancer prevention; clinical care; ethnic diversity; malignant breast neoplasm; member; minority health; minority health disparity; molecular oncology; next generation; precision oncology; prevent; programs; racial diversity

ABSTRACT The Georgetown Lombardi Comprehensive Cancer Center (LCCC) is the only NCI-designated comprehensive cancer center based in the nation’s capital. Led by Louis M. Weiner MD since 2008, LCCC’s vision is to prevent and cure cancer with a local focus and global impact. Our mission is to prevent, treat, and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis, “care for the whole person.” LCCC’s strategic objectives are to 1) advance transformative cancer research, 2) reduce the impact of cancer and diminish disparities in our catchment area, 3) lead high-impact clinical research, 4) ensure long-term growth, vibrancy and stability of the research enterprise, and 5) develop the next generation of cancer scientists, clinicians and educators. These objectives were furthered by LCCC’s deepening relationship with the John Theurer Cancer Center (JTCC) of Hackensack Meridian Health (HMH), a clinical and clinical research powerhouse that brings a substantial research base and extends LCCC’s impact. With this P30 competitive renewal application LCCC is applying as a CCSG consortium with JTCC, which meets CCSG FOA external funding requirements. The LCCC Consortium is comprised of Georgetown Lombardi Comprehensive Cancer Center, based in Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and LCCC-NJ catchment areas. LCCC research is based in four research programs: Breast Cancer (BC), Cancer Prevention and Control (CPC), Experimental Therapeutics (ET) and Molecular Oncology (MO). Crosscutting initiatives in data science, minority health and health disparities, cancer precision medicine, immunotherapy and cancer survivorship focus and support the work of these programs. During the current CCSG funding cycle, LCCC employed a robust strategic planning process to develop and refine its research. LCCC conducts research that is practice changing, paradigm shifting and policy informing, with 114 members publishing 1,390 papers (18% with IF>8) during the current CCSG funding period. Current cancer-focused annual direct cost funding for LCCC members is $36,696,492 (of which $3,282,510 is from members based at LCCC-NJ). LCCC had 2,165 interventional clinical trial accruals from 2014-2017 in its DC catchment area, which consists of more than four million people in DC and each surrounding county in Maryland and Virginia. LCCC’s Bergen County NJ catchment area contains nearly 1 million residents. LCCC has increased opportunities for clinical research and care by serving these large, racially and ethnically diverse catchment areas, which suffer from excess mortality from breast, prostate, pancreas and liver cancers. Future plans include expansion of research addressing catchment areas’ needs, with a particular emphasis on hematologic malignancies and cellular therapy translational and clinical research.

抽象的 乔治城隆巴迪综合癌症中心 (LCCC) 是唯一一家 NCI 指定的综合癌症中心 LCCC 是一家位于美国首都的癌症中心，自 2008 年起由 Louis M. Weiner 医学博士领导，其愿景是预防癌症。 我们的使命是通过联系来预防、治疗和治愈癌症。 科学发现、专家和富有同情心的患者护理、优质教育以及与 LCCC 的战略目标是“关心整个人”。 1) 推进变革性癌症研究，2) 减少癌症的影响并缩小我们之间的差距 服务区域，3) 引领高影响力的临床研究，4) 确保长期增长、活力和稳定性 研究企业，5) 培养下一代癌症科学家、新人和教育工作者。 LCCC 与 John Theurer 癌症中心 (JTCC) 的加深关系进一步推动了我们的目标 Hackensack Meridian Health (HMH) 是一家临床和临床研究巨头，带来了大量的 通过此 P30 竞争性更新申请，LCCC 正在申请作为研究基础并扩大 LCCC 的影响。 CCSG 与 JTCC 联合体，满足 CCSG FOA 外部资金要求。 由位于华盛顿特区的乔治城隆巴迪综合癌症中心 (LCCC-DC) 组成 以及位于新泽西州哈肯萨克的哈肯萨克子午线健康约翰·特雷尔癌症中心 (LCCC-NJ)。 因此，LCCC 服务区域由 LCCC-DC 和 LCCC-NJ 服务区域定义。 研究基于四个研究项目：乳腺癌 (BC)、癌症预防和控制 (CPC)、 数据科学中的实验治疗学 (ET) 和分子肿瘤学 (MO)，少数群体。 健康与健康差异、癌症精准医学、免疫治疗和癌症生存焦点和 在当前的 CCSG 资助周期中，LCCC 采用了强有力的战略。 制定和完善其研究的规划流程 LCCC 开展的研究正在改变实践， 范式转变和政策通报，114 名成员在会议期间发表了 1,390 篇论文（18% 的 IF>8） 当前 CCSG 资助期限为 LCCC 成员以癌症为重点的年度直接费用资助期限。 36,696,492 美元（其中 3,282,510 美元来自 LCCC-NJ 的会员） LCCC 有 2,165 名介入临床患者。 2014 年至 2017 年在其 DC 学区（该地区由超过 400 万人口组成）的试验应计费用 马里兰州和弗吉尼亚州的每个周边县均包含 LCCC 的新泽西州卑尔根县集水区。 LCCC 通过为这些居民提供服务，增加了临床研究和护理的机会。 人口众多、种族和民族多样化的集水区，乳腺癌、前列腺癌、 胰腺癌和肝癌的未来计划包括扩大研究范围以满足流域的需求， 特别强调血液恶性肿瘤和细胞治疗转化和临床研究。